More likely, it reflects the tight focus by Phylogica in targeting the development of antibiotics and cancer drugs through its in-house program and through its collaboration with Genentech.
Yes, agree. I'm interested in how some of these in-house drug candidates with antimicrobial activity that the company have been working on optimising since 2012 are coming along. I wonder what improvements have been achieved since the introduction of these new generation technologies (EET, Synthetic Phylomers and the recent work on Macrocyclic technologies) now firmly in place?
As you know the passage on page 4 of this presentation below has always had my attention.
November 22, 2012 announcement - "Phylogica launches next generation libraries":
The improvements achieved with these next generation Phylomer libraries should enable the discovery of higher quality peptide drug candidates with enhanced drug like characteristics, which should shorten the timelines for lead generation.
Tony
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)